RDNTRadNet, Inc.
Services-Medical Laboratories
- Revenue
- $2.0B
- 12% YoY
- Operating margin
- 3.0%
- 47% YoY
- EBITDA
- $214M
- 12% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 2.9×
- $612M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear3% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear27% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.3B | $1.4B | $1.6B | $1.8B | $2.0B | 12% |
| Operating income | $83M | $46M | $99M | $105M | $62M | 41% |
| Net income | $25M | $11M | $3M | $3M | −$19M | 768% |
| Operating cash flow | $149M | $146M | $221M | $233M | $299M | 28% |
| Stock-based comp | $25M | $24M | $27M | $30M | $55M | 83% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $12M | $9M | 365 | 112 |
| FY2024 | $9M | $16M | 357 | 94 |
| FY2023 | $7M | $10M | 178 | 92 |
| FY2022 | $6M | $6M | 96 | 88 |
| FY2021 | $5M | $5M | 154 | 110 |